About Intraflagellar transport protein 52 homolog
Intraflagellar transport protein 52 homolog (IFT52) is a protein
from Homo sapiens identified by UniProt accession
Q9Y366, 437 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Intraflagellar transport protein 52 homolog |
| UniProt accession | Q9Y366 |
| Gene | IFT52 |
| Organism | Homo sapiens |
| Length | 437 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- short rib-polydactyly syndrome · score 0.73
- cranioectodermal dysplasia · score 0.37
- reticulocyte count · score 0.22
- type 2 diabetes mellitus · score 0.22
- mean corpuscular volume · score 0.20
- reticulocyte measurement · score 0.19
- myeloid white cell count · score 0.19
- mean corpuscular hemoglobin · score 0.14
- mean reticulocyte volume · score 0.12
- Jeune syndrome · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y366-F1 | alphafold | PREDICTED | 84.24 | — |
Amino-acid sequence (437 residues)
MEKELRSTIL FNAYKKEIFT TNNGYKSMQK KLRSNWKIQS LKDEITSEKL NGVKLWITAG PREKFTAAEF EILKKYLDTG GDVFVMLGEG GESRFDTNIN FLLEEYGIMV NNDAVVRNVY HKYFHPKEAL VSSGVLNREI SRAAGKAVPG IIDEESSGNN AQALTFVYPF GATLSVMKPA VAVLSTGSVC FPLNRPILAF YHSKNQGGKL AVLGSCHMFS DQYLDKEENS KIMDVVFQWL TTGDIHLNQI DAEDPEISDY MMLPYTATLS KRNRECLQES DEIPRDFTTL FDLSIFQLDT TSFHSVIEAH EQLNVKHEPL QLIQPQFETP LPTLQPAVFP PSFRELPPPP LELFDLDETF SSEKARLAQI TNKCTEEDLE FYVRKCGDIL GVTSKLPKDQ QDAKHILEHV FFQVVEFKKL NQEHDIDTSE TAFQNNF
Explore Intraflagellar transport protein 52 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets